Zolpidem for persistent insomnia in SSRI-treated depressed patients

Journal of Clinical Psychiatry

Volumn 60, Issue 10, 1999, Pages 668-676

  Asnis, Gregory M ^a   Chakraburtty, Amal ^b   DuBoff, Eugene A ^c   Krystal, Andrew ^d   Londborg, Peter D ^e   Rosenberg, Russell ^f   Roth Schechter, Barbara ^g   Scharf, Martin B ^h   Walsh, James K ⁱ  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b Prof Corporation of Psychiatry   (United States)

^c Center for Behavioral Medicine   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Seattle Surgery Center   (United States)

^f NORTHSIDE HOSPITAL   (United States)

^g Boston Res and Science Consulting   (United States)

^h Ctr for Research in Sleep Disorders   (United States)

ⁱ Sleep Medicine and Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIAZOLAM; ZOLPIDEM; ZOLPIDEM TARTRATE;

ADULT; AGED; ARTICLE; BONE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFLUENZA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SLEEP TIME; WELLBEING;

EID: 0032721861     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n1005     Document Type: Article

References (37)

1. Winokur A, Reynolds CF. The effects of antidepressants on sleep physiology. Prim Psychiatry 1994;Nov/Dec:22-27
2. Akiskal HS. Mood disorders: clinical features. In: Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry, VI. Baltimore, Md: Williams & Wilkins; 1995:1123-1153
3. Reynolds CF, Kupfer DJ. Sleep research in affective illness: state-of-the-art circa 1987. Sleep 1987;10:199-215
4. Nelson JC. Safety and tolerability of the new antidepressants. J Clin Psychiatry 1997;58(suppl 6):26-31
5. Beasley CM, Sayler ME, Weiss AM, et al. Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol 1992;12: 328-333
6. Beasley CM Jr, Domseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991;52: 294-299
7. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin re-uptake inhibitors: meta-analysis of efficacy and acceptability. Br J Med 1993;306: 683-687
8. Bennie EH, Mullin JM, Martindale JJ. Double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995;56:229-237
9. DeWilde J, Spiers R, Mertens C, et al. Double-blind, comparative multicenter study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993;87:141-145
10. Dominguez RA, Jacobson AF, Goldstein BJ, et al. Comparison of triazolam and placebo in the treatment of insomnia in depressed patients. Curr Ther Res 1984;36:856-865
11. Cook MD, Conner J. Retrospective review of hypnotic use in combination with fluoxetine and sertraline. Clin Drug Invest 1995;9:212-216
12. Cohn JB. Triazolam treatment in depressed patients taking tricyclics. J Clin Psychiatry 1983;44:401-406
13. Nolen WA, Haffmans PMJ, Bouvy PF, et al. Hypnotics as concurrent medication in depression. J Affect Disord 1993;28:179-188
14. Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994;151:1069-1072
15. Scharf MB, Roth T, Vogel GW, et al. Multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994;55:192-199
16. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep 1995;18: 246-251
17. Dockhorn D, Dockhorn R. Zolpidem in the treatment of short-term insomnia: a randomized, double-blind, placebo-controlled clinical trial. Clin Neuropharmacol 1996;19:333-340
18. Roth T, Puech AJ, Paiva T. Zolpidem: place in therapy. In: Freeman H, Puech AJ, Roth T, eds. Zolpidem: An Update of Its Pharmacological Properties and Therapeutic Place in the Management of Insomnia. Paris, France: Elsevier; 1996:215-230
19. Unden M, Roth-Schechter B. Next day effects after nighttime treatment with zolpidem: a review. Eur J Psychiatry 1996;11(suppl 1):21S-30S
20. Piergies A, Sweet J, Johnson M, et al. The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Int J Clin Pharm Ther 1996;34:178-183
21. Allard S, Sainati S, Roth-Schechter BF, et al. Minimal interaction between fluoxetine and multiple dose zolpidem in healthy women. Drug Metab Dispos 1998;26:617-620
22. Allard S, Sainati S, Roth-Schechter B. Co-administration of short-term zolpidem with sertraline in healthy women. J Clin Pharmacol 1999;39: 184-191
23. Metz A, Shader RI. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine. Int Clin Psychopharmacol 1990;5:191-194
24. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE Jr, eds. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:235-259
25. Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey Manual and Interpretation Guide. Boston, Mass: New England Medical Center, The Health Institute; 1993
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
27. Thompson C. Mirtazapine versus selective serotonin reuptake inhibitors. J Clin Psychiatry 1999;60(suppl 17):18-22
28. Lahmeyer H, Wilcox CS, Kann J, et al. Subjective efficacy of zolpidem in outpatients with chronic insomnia. Clin Drug Invest 1997;13:134-144
29. Leppik I, Roth-Schechter B, Gray WG, et al. Double-blind placebo-controlled comparison of zolpidem, triazolam and temazepam in elderly patients with insomnia. Drug Dev Res 1997;40:230-238
30. Roehrs T, Vogel G, Roth T. Rebound insomnia: its determinants and significance. Am J Med 1990;88(suppl 3A):39S-42S
31. Roehrs TA, Merlott I, Zorick F, et al. Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation. Psychopharmacology (Berl) 1992;108:67-71
32. Hajak G, Glarenbach P, Fischer W, et al. Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psychiatry Clin Neurosci 1998;248:148-156
33. Lauer CJ, Schreiber W, Holsboer F, et al. In quest of identifying vulnerability markers for psychiatric disorders by all-night polysomnography. Arch Gen Psychiatry 1995;52:145-153
34. Dryman A, Eaton D. Affective symptoms associated with onset of major depression in the community findings from the US National Institute of Mental Health epidemiologic catchment area program. Acta Psychiatr Scand 1991;84:1-5
35. Giles DE, Jarrett RB, Roffwarg HP, et al. Reduced REM latency: a predictor of recurrence in depression. Neuropsychopharmacology 1987;1:33-39
36. Perlis ML, Giles DE, Buysse DJ, et al. Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 1997;42: 209-212
37. Pagot R, Cramer P, L'Heritier C, et al. Comparison of the efficacy and tolerability of zolpidem 20 mg and triazolam 0.5 mg in anxious or depressed insomniac patients. Curr Ther Res 1993;53:88-97